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The incidence of cutaneous melanoma in Germany – as in many
other parts of the world – has increased steadily throughout the
past decades. Presuming an incidence of 15 melanomas per
100 000 inhabitants, around 12 000 new cases will be expected in
Germany in 1998 and more than 2000 of those patients will die
within the next 5 years from metastatic disease. Prognostic factors
like Breslow’s tumour thickness, location of the primary tumour
and patient’s sex are well established (Balch et al, 1985). However,
individual tumour markers for malignant melanoma are lacking so
far. Such individual markers would be of particular value in
monitoring the therapeutic efficacy of relatively toxic adjuvant
treatment schedules (Kirkwood et al, 1996) or could serve as
stratification factors in prospective clinical trials.
At present, in haematology as well as in oncology, efforts of
many research programmes are focused on the early detection of
micrometastases, circulating malignant cells or early cancer
relapses. Promising concepts like the detection of tumour-specific
gene mutations or tissue-specific transcripts, allowing recognition
of one tumour cells within 10 ml of blood (Brossart et al, 1993) or
within 10 million of peripheral blood mononuclear cells (PBMCs)
(Ghossein et al, 1998) have evolved. Most authors were able to
detect one tumour cell in the background of 106 mononucleated
cells (Kunter et al, 1996; Mellado et al, 1996; Reinhold et al,
1997). In melanoma disease, tyrosinase, the key enzyme of
melanin biosynthesis (Kwon et al, 1987; Ponnazhagen et al, 1994)
was the first tissue-specific transcript to be detected in peripheral
blood (Smith et al, 1991), bone marrow (Ghossein et al, 1996),
draining lymph nodes (Wang et al, 1994; Schwürzer-Voit et al,
1996; Van der Velde et al, 1996) and in the subcutaneous fat adja-
cent to primary tumours as well (Proebstle et al, 1996). Since the
original description of a reverse transcription polymerase chain
reaction (RT-PCR) method for detection of tyrosinase transcripts
in peripheral blood (Smith et al, 1991), controversial data have
been reported in terms of sensitivity of this method and its clinical
relevance (Brossart et al, 1993, 1994; Battayani et al, 1995; Foss
et al, 1995; Hoon et al, 1995; Pitman et al, 1996; Gläser et al,
1997; Jung et al, 1997; Farthmann et al, 1998; Ghossein et al,
1998). Striking differences have been reported concerning the
detected proportion of tyrosinase-positive patients varying, e.g. in
stage IV patients, actually from zero (Foss et al, 1995) to 100%
(Brossart et al, 1993). Disease-free and overall survival in correla-
tion with RT-PCR tests have so far been rarely addressed (Kunter
et al, 1996; Mellado et al, 1996; Ghossein et al, 1998).
In this study, we examined 212 blood samples from 212
melanoma patients with all clinical stages. Blood samples were
obtained as patients presented for routine tumour follow-up.
RT-PCR results were associated with clinical tumour stage at the
time of blood sampling, furthermore with disease-free and overall
survival intervals, as well as with established risk factors like sex
and primary tumour location.
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Summary The clinical value of the reverse transcription polymerase chain reaction (RT-PCR) assay for tyrosinase in peripheral blood of
melanoma patients is still under debate. A total of 212 blood samples from 212 melanoma patients in all clinical stages (AJCC) were
examined. Erythrocytes were lysed prior to RNA extraction by phenol precipitation from 2.7 ml of blood. cDNA for tyrosinase PCR was
synthesized using random hexamers. Positive tyrosinase RT-PCR results were obtained in 11% of 106 stage I patients, 18% of 56 stage II
patients, 31% of 26 stage III patients and 67% of 24 stage IV patients. After a median follow-up of 36 months (range 26–41), stage III patients
with positive RT-PCR for tyrosinase had a shortened disease-free interval as compared to negative patients (P < 0.01). In stage IV patients,
median overall survival was 8 months in case of a positive RT-PCR in contrast to 12 months in case of a negative test. While univariate
analysis showed sex and primary tumour location associated with positive RT-PCR, multiple regression analysis revealed clinical stage and
detection of tyrosinase transcripts in peripheral blood as best prognostic factors. Hazard ratios for disease-free survival were 19.7 (confidence
interval (CI) 8.53–45.5, P = 0.0001) for metastatic vs primary disease and 2.96 (Cl 1.49–5.89, P = 0.002) for positive vs negative tyrosinase
RT-PCR. The corresponding hazard ratios for overall survival were 97.0 (Cl 12.7–741, P = 0.0001) and 4.33 (Cl 1.69–11.1,
P = 0.002). Our results emphasize the importance of tyrosinase RT-PCR testing in peripheral blood. © 2000 Cancer Research Campaign
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MATERIALS AND METHODS
Patients, staging and processing of blood samples
Samples of 2.7 ml EDTA blood were taken from 212 melanoma
patients with all clinical stages. Twenty millilitres of erythrocyte-
lysis (EL) buffer were added within 1 h. The mixture was kept on
ice for 15 min and subsequently centrifuged at 1000 rpm for
10 min at 4°C. The pellet was resuspended in 20 ml EL buffer for
5 min on ice, before centrifugation was repeated. One millilitre of
guanidinium-iso-thiocyanate (GIT) buffer was added to the pellet.
The sample was stored at –85°C until further analysis.
All blood sampling procedures were performed concomitantly
to a tumour staging procedure as patients presented for melanoma
follow-up. This design was chosen to allow evaluation of the prog-
nostic value of tyrosinase RT-PCR for all-day usage in routine
follow-up of melanoma patients. The staging interval and the
extent of the staging schedule depended on the current stage of
melanoma disease. Routine staging intervals were 12 months for
stage IA patients, 6 months for stage IB patients and 3 months for
stage II–IV patients. A routine staging procedure included
physical examination and ultrasound B-scan of regional soft
tissues, detecting more than 90% of the relapses. Ultrasound
B-scan of the abdomen and chest X-ray were added once a year for
stage I and stage II patients, twice yearly for stage III patients and
every 3 months in stage IV patients. Computerized tomography
(CT) or magnetic resonance tomography (MRT) scans of the brain,
thoracic, abdominal and pelvic organs was performed every
3 months in stage IV patients, at the first clinic visit of stage II–IV
patients and whenever a patient had disease progression by tumour
stage.
RNA preparation and reverse transcription
Total RNA was isolated according to the method of Chomczynski
and Sacchi (1987), and eventually extracted in 60 ml of DEPC
water. RNA was analysed at 260 and 280 nm using a spectral
photometer. Total yield and purity of the samples were determined
before reverse transcription. Isolated RNA was immediately
processed or stored at –85°C. Reverse transcription was performed
using the superscript preamplification kit (Gibco-BRL). A total of
1.5 mg of RNA were transcribed by means of 50 ng of random
hexamers, 10 mM dNTO-mix and 200 units of superscript II RT
(Gibco-BRL Inc., Grand Island, NY, USA). The isolated cDNA
was further processed or stored at –20°C.
Nested PCR for tyrosinase
To avoid contamination, reaction mixtures were prepared using a
laminar air flow. Primers for tyrosinase-PCR, designed for a
nested PCR, were applied as previously described (Smith et al,
1991). The outer primers HTYR1 (TTG GCA GAT TGT CTG
TAG CC) and HTYR2 (AGG CAT TGT GCA TGC TGC TT)
amplified a product of 284 base pairs. Two microlitres of the
previously obtained cDNA sample were added to 5 ml of the
tenfold concentrated PCR buffer, 5 ml of 10 mM nucleotides
(dATP, DCTP, dTTP, dGTP), 0.4 ml of the primers HTYR1 and
HTYR2 (100 pmol l–1) and finally aqua bidest was added to a total
volume of 50 ml. The PCR-protocol was then initiated on a
thermocycler starting with 5 min at 94°C, first hold at 80°C,
followed by addition of 1 U (5 U ml–1) Taq polymerase (Gibco).
Each of the following 30 cycles involved a first step at 94°C
for 45 s, a subsequent step at 60°C for 45 s and a third step at 72°C
for 45 s. After 30 cycles a final delay followed by 5 min at a
temperature of 72°C and further 5 min at 30°C. One microlitre of
this outer PCR product was then diluted 1:100. Five microlitres of
this solution were used for the second inner amplification cycle.
The nested PCR was carried out in the same way as the primary
PCR, inner primers HTYR3 (GTC TTT ATG CAA TGG TT) and
HTYR4 (GCT ATC CCA GTA AGT GGA CT) were applied in the
same concentration. Ten microlitres of the final product (207 bp)
of the second inner PCR were analysed on a 2%-agarose gel (90 V,
80 min). On each gel, length standards (100 bp ladder, Gibco), as
well as positive and negative controls were run in parallel to
patients’ samples (Figure 1).
Specificity and housekeeping enzyme
Specificity of the RT-PCR products was confirmed by a non-
isotopic Southern blot hybridization procedure. A digoxigenin-
labelled oligonucleotide probe was derived from the inner parts of
amplified inner fragment. For hybridization and chemiluminiscent
detection a commercially available kit (Lumigen PPD, Boehringer
Mannheim, Germany) was used. The housekeeping enzyme glyc-
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Figure 1 (A) Disease-free survival of stage III patients calculated from the
time of blood sampling displayed according to the method of Kaplan and
Meier. Log-rank testing revealed statistical significance at a level of P < 0.01.
The median follow-up interval is 36 months. (B) Overall survival of stage IV
patients calculated from the time of blood sampling. Differences were not
significant (P = 0.33). The follow-up intervals of censored patients are tick-
marked. One tyrosinase-positive patient died 1 month after blood sampling
from pneumonia120 TM Proebstle et al
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eraldehyde 3-phosphatase dehydrogenase (GAPDH) was used to
test for integrity of the isolated RNA. Thirty PCR cycles were
performed using the primers GAPDH 321 (ACCACAGTCCAT-
GCCATCAC) and GAPDH 55 (TGCCAGCCCCAGCGT-
CAAAG). Only GAPDH-PCR-positive samples were evaluated,
negative samples were considered to be non-informative.
Additional control experiments
Sensitivity of the method was high enough to detect tyrosinase
transcripts in 10 ml of control blood spiked with 10 SkMel28 cells
(Figure 2). Additionally, blinded samples were successfully
examined in the setting of the quality control initiative of the
EORTC-Melanoma Cooperative Group (23).
Statistics
Survival data were displayed as Kaplan–Meier estimates and
compared between subgroups of patients using logrank tests. To
assess the association between RT-PCR results and clinical stage,
the Cochrane–Armitage trend test was used. To compare RT-PCR
results with respect to patient’s sex or site of the primary tumour,
Mantel–Haenszel estimates of odds ratios and their 95% confi-
dence intervals (CIs) were calculated, taking into account the strat-
ification according to the clinical stages. All P-values are given
two-sided. Multiple Cox regression was applied with backward
elimination (significance level of 0.10) for selection of prognostic
factors. The statistical analyses were performed with the Statistical
Analysis System (SAS 1989) and StatXact (Version 3.0.2, 1996).
RESULTS
A total of 212 blood samples were obtained from 212 melanoma
patients with all clinical stages as they presented for routine
tumour follow-up. Characteristics of included patients are
displayed in Table 1, representing a profile of a typical follow-up
cohort of melanoma patients. As expected, patients in early clin-
ical stages were represented at a higher proportion, and likewise
female sex was observed more frequently (57%). Furthermore, the
proportion of different histologic melanoma subtypes and the sites
of the primary tumours indicate that a typical follow-up cohort of
melanoma patients was studied.
Clinical stage, sex and site of the primary tumour –
univariate statistical analysis
Overall, 46 of 212 blood samples (21.7%) were positive for tyrosi-
nase RT-PCR. Positive results were obtained in 11% of stage I
patients (n = 106), 18% of stage II patients (n = 56), 31% of stage
III patients (n = 26) and 67% of stage IV patients (n = 24) as shown
in Table 2, revealing a pronounced stage dependence (P = 0.0001,
Cochrane–Armitage). In addition, results were separately shown
for females and males with respect to their clinical stage at time of
blood sampling (Table 2). Remarkably enough, in all clinical
stages, male patients showed a tendency towards higher rates of
positivity for tyrosinase RT-PCR as opposed to female patients.
The odds ratios listed in Table 2 demonstrate this fact. Overall, a
positive RT-PCR was observed in 26 out of 90 male patients
(28.9%) as compared to 20 out of 122 female patients (16.4%).
The common odds ratio for a positive RT-PCR was 2.15 (P < 0.05)
for males versus females, accounting for stratification for clinical
stages (CI 1.05–4.40).
Table 1 Patients characteristics according to clinical stages of malignant
melanoma
Clinical stage I II III IV All stages
(AJCC)
Number of 106 56 26 24 212
patients
Female sex 61 (58%) 33 (59%) 16 (62%) 12 (50%) 122 (58%)
Site of the
primary tumour
Limb 60 38 14 13 125
TNS 46 18 12 11 87
Histological type
of the primary
tumour
SSM 80 15 6 6 107
NM 11 33 8 7 59
ALM 2 5 4 2 13
LMM 11 2 0 0 13
Others 2 1 8 9 20
Age, median 53 58 57 54 55
(range) (23–85) (20–85) (25–83) (23–83) (20–85)
aTNS = trunk, neck, scalp and other primary tumour locations. bOthers:
ocular melanoma, mucosal melanoma or melanoma of unknown origin.
SSM = superficial spreading melanoma, NM = nodular melanoma,
ALM = acrolentiginous melanoma, LMM = lentigo maligna melanoma.
Table 2 Clinical stage of patients positively tested by RT-PCR for tyrosinase discriminated for sex and the location of the primary tumour
Clinical stage (AJCC) I II III IV All stages Statistical
significance
Positive patients/all patients 12/106 10/56 8/26 16/24 46/212 P < 0.0001
(11.3%) (17.9%) (30.8%) (66.6%) (21.7%)
Positive test of males /total number  6/45 5/23 6/10 9/12 26/90 P < 0.05
of males.
Odds ratio male vs female OR = 1.41 OR = 1.56 OR = 10.5 OR = 2.14 common OR = 2.15
Confidence interval (0.42–4.70) (0.39–6.14) (1.50–73.7) (0.38–12.2) (1.05–4.40)
Positive test of limb tumours /total 4/60 6/38 4/14 7/13 21/125 P < 0.05
number of limb tumours
Odds ratio limb vs not limb OR = 0.34 OR = 0.66 OR = 0.80 OR = 0.26 common OR = 0.46
Confidence interval (0.10–1.21) (0.16–2.70) (0.15–4.25) (0.04–1.70) (0.22–0.96)
OR = odds ratio.Prognostic relevance of Tyr-RT-PCR in melanoma 121
British Journal of Cancer (2000) 82(1), 118–123 © 2000 Cancer Research Campaign
A similar observation was made comparing patients with
primary melanomas on the limbs to patients with other primary
tumour sites (Table 2). Patients with primary tumours on the limb
showed a decreased risk to be tyrosinase positive in contrast to the
other patients. Only 21 out of 125 melanoma patients with limb
location of the primary tumour had positive test results (16.8%),
while 25 out of 87 patients (28.7%) with other primary tumour
sites had tyrosinase transcripts in their peripheral blood. The
common odds ratio for clinical stages was 0.47 (P < 0.05) in
favour of patients with primaries on the limb (CI 0.22–0.96). An
association between any histological tumour type and a positive
RT-PCR for tyrosinase was not detectable (data not shown).
Association of positive RT-PCR assay and survival
During follow-up after PCR-blood testing, 23 of 25 melanoma
relapses in stage I–III patients were detected by physical examina-
tion or ultrasound B-scan. Skin or regional soft tissues were
affected with or without involvement of other organs. Only two
stage III patients skipped the soft tissue compartment with tumour
progression and became symptomatic from distant metastases.
One patient developed headache 20 months after having been
tested negative for blood-tyrosinase. Staging revealed multiple
brain metastases causing death another 5 months later. The second
patient showed dyspnoea 4 months after having been tested posi-
tive for blood-tyrosinase and died 3 months later from diffuse
pulmonary metastases. However, CXR and abdominal ultrasound
were negative at the time of blood sampling.
The median follow-up interval after blood sampling was 36
months for all patients (range 26–41 months). Disease-free
survival was not evaluated for stage I or stage II patients, because
only two and nine recurrences respectively, occurred in these
groups. Disease-free intervals of patients with clinical stage III at
time of blood sampling are displayed according to the method of
Kaplan and Meier (Figure 1A), revealing a difference between
patients with positive and negative tyrosinase RT-PCR (P < 0.01,
log-rank). In the positively tested group only one patient is still
without relapse since blood sampling for tyrosinase RT-PCR
(disease-free interval: 27+ months) while the seven remaining
patients meanwhile all had disease recurrences. Remarkably, in the
negatively tested group only seven of 18 patients relapsed until to
date.
Analysis of the overall survival interval from the time of blood
sampling was only performed in stage IV patients (Figure 1B).
Median survival of RT-PCR-positive patients was 8 months as
compared to 12 months in the negative group, however, because of
the limited number of patients this difference observed was not
statistically significant (P = 0.33).
Multiple regression analysis
To establish a model for prognosis of disease-free and overall
survival, a multiple regression analysis with subsequent backward
selection procedure was performed on all 212 patients including
the following parameters: clinical stage (AJCC) of the patients
(stage I or II versus stage III or IV), result of tyrosinase RT-PCR
blood testing (positive versus negative), sex (female versus male),
site of the primary tumour (limb location versus other locations)
and histological subtype of the primary tumour (superficial
spreading melanoma versus nodular melanoma versus others).
Table 3 A and B show the results for relapse-free and overall
survival. Out of these variables, clinical stage and the result of the
tyrosinase RT-PCR are sufficient to give a prognosis on survival.
All other parameters provide no additional information.
DISCUSSION
Tyrosinase RT-PCR has been shown to facilitate the detection of
melanoma cells in surgically removed lymph nodes (Wang et al,
1994), and in fine-needle aspirates as well (Schwürzer-Voit et al,
1996). In contrast, data published on tyrosinase RT-PCR of
peripheral blood from melanoma patients are heterogeneous and
sometimes inconclusive.
Sensitivity of the tyrosinase RT-PCR
Generally, the sensitivity of control experiments has been
described by most authors to be extremely high (Brossart et al,
1993; Kunter et al, 1996; Mellado et al, 1996; Reinhold et al,
1997; Ghossein et al, 1998) detecting one melanoma cell in 10 ml
blood of healthy donors. However, analysis of blinded spiked
samples revealed that such results might not be achieved routinely
in all laboratories and a sensitivity of ten melanoma cells in 10 ml
of blood is realistic (Keilholz et al, 1998). Detection rates for
tyrosinase transcripts in peripheral blood of stage IV patients are
described between zero (Foss et al, 1995) and 100% (Brossart
et al, 1993) but are most likely due to technical differences. RNA
extraction was performed from whole blood samples (Brossart et
al, 1993; Foss et al, 1995; Kunter et al, 1996; Pitman et al, 1996;
Van der Velde, 1996), from Ficoll separated fractions (Battayani
et al, 1995; Hoon et al, 1995; Mellado et al, 1996; Reinhold et al,
1997; Ghossein et al, 1998) or following lysis of erythrocytes as
described in the present study. RNA extraction was reported
utilizing phenol precipitation of total RNA (Smith et al, 1991;
Brossart et al, 1993; Hoon et al, 1995; Mellado et al, 1996; Jung
et al, 1997; Reinhold et al, 1997) as well as following column
purification of mRNA (Battayani et al, 1995; Van der Velde et al,
1996). Even data obtained by heterogeneous methods and by
different PCR protocols, have been pooled within one report
(Gläser et al, 1997).
Specificity of tyrosinase RT-PCR
Mainly reports of very high sensitivities have raised doubts
regarding the method’s specificity and problems resulting from
Table 3 Parameters affecting the survival intervals of 212 melanoma
patients as selected by multiple Cox regression analysis. A. Disease-free
survival. B. Overall survival
Hazard 95% confidence P-values
ratio interval
A
Clinical stage (AJCC)
I or II (reference) 1.0
III or IV 19.7 (8.52–45.5) P = 0.0001
Positive tyrosinase RT-PCR
in peripheral blood 2.96 (1.49–5.89) P = 0.002
B
Clinical stage (AJCC)
I or II (reference) 1.0
III or IV 97.0 (12.7–741) P = 0.0001
Positive tyrosinase RT-PCR
in peripheral blood 4.33 (1.69–11.1) P = 0.002122 TM Proebstle et al
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carry-over contamination have already been reported (Foss et al,
1995). However, positive tyrosinase RT-PCR results are usually
not reported with regard to blood samples obtained from healthy
control patients, from patients with benign diseases or from
patients with non-melanoma diseases respectively (Brossart et al,
1993; Battyani et al, 1995; Hoon et al, 1995; Kunter et al, 1996).
Besides examination of such control patients, testing of a typical
set of follow-up patients with all clinical stages is helpful, since
substantial carry-over contamination would affect all clinical
stages in the same way and could thus be recognized.
Univariate analysis – association with clinical stage,
sex and primary tumour site
Despite large differences in sensitivity of tyrosinase RT-PCR,
several authors reported a correlation of positive test results with
clinical stages (Brossart et al, 1993, 1994; Battyani et al, 1995;
Hoon et al, 1995; Kunter et al, 1996; Mellado et al, 1996;
Farthmann et al, 1998) as we also observed (Table 2). In our study
the rate of positive tests in stage IV patients was 67% (95% CI
44.6–84.4%), which is higher than the rates reported by many
other authors. Most descriptions report rates below 30% for stage
IV patients (Foss et al, 1995; Kunter et al, 1996; Pitman et al,
1996; Gläser et al, 1997; Jung et al, 1997) but also higher rates are
described with 94% (Mellado et al, 1996) or even 100% (Brossart
et al, 1993). In our study, the volume of peripheral blood examined
was only 2.7 ml which is the lowest volume reported so far. Our
finding of 11% and 18% positive patients in stage I and II respec-
tively, corroborates already reported data between 10 and 25% for
these stages (Brossart et al, 1993; Battyani et al, 1995; Mellado
et al, 1996; Ghossein et al, 1998).
The question whether increased mortality rate of males (Balch
et al, 1985) is reflected by tyrosinase RT-PCR so far has been
addressed by only one study (Farthmann et al, 1998) finding a non-
significant trend. Our study (Table 2) showed an odds ratio of
OR = 2.15 for a positive RT-PCR in males (P < 0.05).
A very recent study (Farthmann et al, 1998) reported a signifi-
cantly increased proportion of positive RT-PCR results in patients
with nodular melanoma, with unknown primary tumour or with
non-classifiable primary melanoma as compared to patients with
other types. Our results (data not shown) did not confirm this
finding.
Another known prognostic factor for survival, the site of the
primary tumour, so far has not been evaluated in conjunction with
tyrosinase RT-PCR in peripheral blood. We observed a decreased
risk for positive RT-PCR in peripheral blood of patients with limb
located primary tumours (OR = 0.46, P < 0.05) as compared to
patients with other primary tumour sites (Table 2).
Significance of positive tyrosinase RT-PCR for survival
Obviously, tyrosinase RT-PCR results obtained from analysis of
peripheral blood samples, have to be reviewed upon their prog-
nostic importance in the context of clinical follow-up of melanoma
patients. So far, only few studies were able to address this topic on
the basis of sufficiently long follow-up periods (Kunter, et al,
1996; Mellado et al, 1996, Ghossein et al, 1998). A significantly
decreased disease-free interval was reported for 39 pooled stage II
and stage III patients (Mellado et al, 1996). Recently, a signifi-
cantly reduced overall survival interval was described in stage II
patients as well as in stage III patients with tyrosinase RT-PCR
positive assays (Ghossein et al, 1998). Concerning the overall
survival of stage IV patients, a significant reduction was shown for
tyrosinase-positive patients with visceral metastases (Kunter et al,
1996) while for the undivided cohort of stage IV patients such an
association was not shown (Ghossein et al, 1998). Analysing blood
samples, which were obtained from stage IV patients at first
opportunity, no significantly different overall survival intervals
were detected comparing tyrosinase RT-PCR positive and negative
patients.
In stage III patients our tyrosinase RT-PCR results showed a
strong association to disease-free survival. Within a median
follow-up of 36 months after blood sampling all tyrosinase-
positive patients relapsed, except one, while in the tyrosinase-
negative group only seven of 18 patients had recurrences
(Figure 1A). The clinical value of tyrosinase RT-PCR therefore
should be greatest when testing this group of stage III patients.
Multiple regression analysis
Frequently, statistical associations are reported without consid-
ering other important factors simultaneously. According to our
multiple regression model on all 212 patients at least sex and
primary tumour site were of no independent prognostic importance
for disease-free and overall survival intervals. Both parameters
had shown an association in univariate analysis with the detection
of tyrosinase transcripts in peripheral blood. This is most likely the
reason for the superior significance of RT-PCR results in multiple
regression analysis. Sex and the site of the primary tumour are
no longer significantly associated with survival intervals once
RT-PCR is taken into account.
Therefore, clinical stage and the result of the blood tyrosinase
RT-PCR comprised the whole information for prognosis in our
study (Table 3). These results definitively underscore that multiple
regression models are useful to identify valid prognostic factors.
ACKNOWLEDGEMENTS
For expert help and discussions on technical procedures to Prof. J.
Knop, Martina Willhauck and Ulrike Leiter.
REFERENCES
Balch CM, Soong SW and Shaw HM (1985) An analysis of prognostic factors in
4000 patients with cutaneous melanoma. In: Cutaneous Melanoma: Clinical
Management and Treatment Results Worldwide, Balch CM and Milton GW
(eds), pp. 321–352. Lippincott: Philadelphia
Battyani Z, Grob JJ, Xerri L et al (1995) Polymerase chain reaction of circulating
melanocytes as a prognostic marker in patients with melanoma. Arch Dermatol
131: 443–447
Brossart P, Keilholz U, Willhauck M, et al (1993) Hematogenous spread of malignant
melanoma cells in different stages of disease. J Invest Dermatol 101: 887–889
Brossart P, Keilholz U, Scheibenbogen C, et al (1994) Detection of residual tumour
cells in patients with malignant melanoma responding to immunotherapy.
J Immunother 15: 38–41
Farthmann B, Eberle J, Krasagakis K, Gstöttner M, Wang N, Bisson S and Orfanos
CE (1998) RT-PCR for tyrosinase-mRNA-positive cells in peripheral blood:
evaluation strategy and correlation with known prognostic markers in 123
melanoma patients. J Invest Dermatol 110: 263–267
Foss AJE, Guille MJ, Occleston NL, et al (1995) The detection of melanoma cells in
peripheral blood by reverse transcription-polymerase chain reaction. Br J
Cancer 72: 155–159Ghossein RA, Coit D, Brennan M, Zhang ZF, Wang Y, Bhattacharya, Houghton A
and Rosai J (1998) Prognostic significance of peripheral blood and bone
marrow tyrosinase messenger RNA in malignant melanoma. Clin Cancer Res
4: 419–428
Gläser R, Rass K, Seiter S, et al (1997) Detection of ciculating melanoma cells by
specific amplification of tyrosinase complementary DNA is not a reliable
tumor marker in melanoma patients: a clinical two-center study. J Clin Oncol
15: 2818–2825
Hoon DSB, Wang Y, Dale PS, et al (1995) Detection of occult melanoma cells in
blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol
13: 2109–2115
Jung FA, Buzaid AC, Merrick IR, et al (1997) Evaluation of tyrosinase mRNA as a
tumor marker in the blood of melanoma patients. J Clin Oncol 15: 2826–2831
Keilholz U, Willhauck M, Rimoldi D, et al (1998) Reliability of reverse
transcription-polymerase chain reaction (RT-PCR)-based assays for the
detection of circulating tumor cells: a quality-assurance initiative of the
EORTC Melanoma Cooperative Group. Eur J Cancer 34: 750–753
Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Bordern EC and Blum RH
(1996) Interferon-alfa-2b adjuvant therapy of high risk resected cutaneous
melanoma: the eastern cooperative oncology group trial EST 1684. J Clin
Oncol 14: 7–17
Kunter U, Buer J, Probst M, et al (1996) Peripheral blood tyrosinase messenger
RNA detection in malignant melanoma. J Natl Cancer Inst 889: 569–570
Kwon BS, Haq AK, Pomerantz SH, et al (1987) Isolation and sequence of a cDNA
clone for human tyrosinase that maps at the mouse c-albino locus. Proc Natl
Acad Sci USA 84: 7473–7477
Mellado B, Colomer D, Castel T, et al (1996) Detection of circulating neoplastic cells
by reverse transcriptase polymerase chain reaction in malignant melanoma:
association with clinical stage and prognosis. J Clin Oncol 14: 2091–2097
Pitman K, Burchill S, Smith B, et al (1996) Reverse transcriptase polymerase chain
reaction for expression of tyrosinase to identify malignant melanoma cells in
peripheral blood. Annal Oncol 7: 197–201
Ponnazhagen S, Hou L and Kwon BS (1994) Structural organization of the human
tyrosinase gene and sequence analysis and characterization of its promoter
region. J Invest Dermatol 102: 744–748
Proebstle T, Huber R, Sterry W (1996) Detection of early micrometastases in
subcutaneous fat of primary malignant melanoma patients by identification of
tyrosinase mRNA. Eur J Cancer 32A: 1664–1667
Reinhold U, Lüdke-Handjery HC, Schnautz S, et al (1997) The analysis of tyrosinase-
specific mRNA in blood samples of melanoma patients by RT-PCR is not a
useful test for metastatic tumor progression. J Invest Dermatol 108: 166–169
Schwürzer-Voit M, Proebstle TM and Sterry W (1996) Identification of lymph node
metastases by use of PCR in melanoma patients. Eur J Cancer 32A:264–268
Smith B, Selby P, Southgate J, et al (1991) Detection of melanoma cells in peripheral
blood by means of reverse transcriptase and polymerase chain reaction. Lancet
338: 1227–1229
Van der Velde, Zimmermann D, Roijers JF, Bouwens-Rombuds A, et al (1996)
Molecular test for the detection of tumor cells in blood and sentinel nodes. Am
J Pathol 149: 759–764
Wang X, Heller R, VanVoorhis N, et al (1994) Detection of submicroscopic lymph
node metastases with polymerase chain reaction in patients with malignant
melanoma. Ann Surg 220: 768–774
Prognostic relevance of Tyr-RT-PCR in melanoma 123
British Journal of Cancer (2000) 82(1), 118–123 © 2000 Cancer Research Campaign